.png){kind=small}
Research
Impact of the Research Programs We Support
Advancing Care, Innovation, and Research for Inflammatory Bowel Disease
Mount Sinai is one of the world’s undisputed leaders advancing IBD research globally combined with the largest footprint of IBD patients in the U.S., with over 10,000 people cared for annually. Our goal at this moment is twofold: First to catch those with IBD as early as possible, to treat and target the disease with absolute precision, personalizing therapies to an individual’s genetic makeup, quieting the disease throughout their life while optimizing health and wellness. Second, to prevent IBD from developing in the first place. These aims are within our grasp, and we are pursuing them while working to end IBD for all. Our work will catalyze stunning insights and knowledge, moving the entire field forward, towards this ultimate goal. Click here to continue reading.
The Precision IBD Program at Mount Sinai
We have been supporting the research of Mount. Sinai in New York for several years. In 2023, we supported Dr. Marla Dubinsky and Dr. Elizabeth A. Spencer at Mount Sinai in their work to enhance precision care in IBD clinics globally. Their research focuses on identifying genetic factors that affect treatment responses and eliminating unnecessary medication trials for patients. These projects have the potential to transform patient care and improve IBD management. To read about the work, click here.
The Pediatric Inflammatory Bowel Disease (IBD) Program, Dr. Shervin Rabizadeh, MD, MBA
Research Projects Supported by Connecting to Cure Crohn’s and Colitis:
The Pediatric IBD Program at Cedars-Sinai Medical Center continues to thrive as the premier center in both clinical work and research for children with Crohn’s disease and ulcerative colitis—known collectively as IBD.
The continued contributions of Connecting to Cure Crohn’s and Colitis have been critical to the mission of the Cedars-Sinai Pediatric IBD Program in advancing research objectives. The program has a multitude of ongoing research projects and the ones listed below have been most directly impacted.
Click here to continue reading.
The Inflammatory Bowel Disease (IBD) Program at Mayo Clinic, Dr. William Faubian, JR, MD
We are supporting research by Dr. William Faubion and Dr. Laura Raffals called “Defining IBD Disease Phenotypes.” The goal of their work is to develop a complete multi-omics data resource for IBD. Through integration of multi-dimensional molecular phenotyping of patients with IBD, they will resolve underlying pathophysiologic mechanisms enabling precision individualized therapy. Their work involves a data generation and analysis strategy combining genome-wide sequencing technologies, microbial metabolomics, and a functional cellular immune response platform on stool and cells isolated from patients. They hypothesize that multi-parameter data integration of the same exquisitely phenotyped patient will reveal distinct immunologic and microbial-induced pathways/molecular signatures determining IBD severity.
Their collection and integration of datasets will serve as the basis for hypothesis-generating and discovery-based science aimed at identifying molecular predictors of IBD. Integrated, multi-dimensional molecular barcodes of disease will foster breakthroughs in therapeutic stratification to guide improved, predictable, more cost-effective outcomes.